New Delhi [India], Serum Institute of India (SII) has stopped manufacturing and supplying additional doses of Covishield from December 2021 in view of significantly reduced demand for the previous vaccines, a spokesperson of the vaccine manufacturing company said, "India With the target of achieving higher vaccination rates in 2021 and 2022, with the emergence of new mutant type strains, the demand for the previous vaccine reduced significantly, as a result, from December 2021, we stopped manufacturing and supplying additional doses of Covishield On the alleged side effects of the vaccine, SII said it has disclosed all rare to very rare side effects in its packaging since 2021. "It is important to understand and emphasize our commitment to transparency and safety. From the very beginning, we have disclosed all rare to very rare side effects, including thrombosis with thrombocytopenia syndrome, in the packaging insert in 2021," SII spokesperson Said on AstraZeneca's withdrawal of its Covid-19 vaccine Vaxzervaria. India's spokesperson said that the safety of its vaccine remains paramount. Despite the challenges faced during the global pandemic, vaccine safety remains paramount. Be it AstraZeneca's Vaxzervri or our own Covishield, both the vaccines have been instrumental in saving millions of lives across the world. We appreciate the collaborative efforts of governments and ministries in facilitating an integrated global response against the pandemic, the SI spokesperson said.